{"id":"NCT00795821","sponsor":"Eli Lilly and Company","briefTitle":"A Study in Adult Patients With Major Depressive Disorder","officialTitle":"A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2008-12","primaryCompletion":"2010-02","completion":"2011-03","firstPosted":"2008-11-21","resultsPosted":"2018-03-20","lastUpdate":"2018-03-20"},"enrollment":495,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Depressive Disorder, Major"],"interventions":[{"type":"DRUG","name":"LY2216684","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"LY2216684","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess whether LY2216684 is superior to placebo in the treatment of adult patients with major depressive disorder.","primaryOutcome":{"measure":"Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) at Week 10","timeFrame":"Baseline, Week 10","effectByArm":[{"arm":"LY2216684","deltaMin":-13.3,"sd":0.563},{"arm":"Placebo","deltaMin":-9.82,"sd":0.544}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":22},"locations":{"siteCount":37,"countries":["United States","Argentina","Finland","Poland","Russia"]},"refs":{"pmids":["27685842"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":250},"commonTop":["Headache","Nausea","Hyperhidrosis","Insomnia","Constipation"]}}